Analyst Just Declared Lilly the Clear Winner at ADA Conference
The ADA conference spotlighted Lilly and Novo Nordisk in the GLP-1 race. This deep dive explains what the claims mean...
Novo Nordisk
This tag page aggregates 4 Novo Nordisk articles, covering stock moves, drug updates, investor sentiment, and Wegovy pricing. Learn how these factors may shape your portfolio.
20 articlesNovo Nordisk's Wegovy Pill: Is Wall Street Missing Something Behind 3 Million Prescriptions?
A new milestone for obesity treatment arrives as Novo Nordisk's Wegovy Pill hits 3 million prescriptions. This articl...
Lilly Novo Nordisk: Better Weight-Loss Stock Outlook
Two pharma giants sit at the center of the booming weight-loss drug market. This piece breaks down which could offer ...
Lilly Novo Nordisk Battle Intensifies as Obesity Drugs Surge
Eli Lilly's Q1 2026 results slam the lid on the GLP-1 duopoly's early calm, with Lilly’s revenue exploding and Novo N...
Novo Nordisk Beating Lilly in Obesity Pill Market: What It Means for Investors
Novo Nordisk is gaining ground on Lilly in the obesity pill market. This article breaks down the drivers, the competi...
This News From Novo: A Warning for Eli Lilly Shareholders
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Forget Oral Wegovy: This Could Be a Bigger Win for Investors
The launch of oral Wegovy marked a turning point for weight-loss drugs and stock investors. But a newer, rival oral G...
Is Down Near 5-Year Low a Cheap Novo Nordisk Stock?
Novo Nordisk has drifted toward a five-year low, raising questions about value vs. risk. This guide breaks down the f...
Novo Nordisk Stock Outlook 2026–2030: Forecasts and Risks
Analysts project a multi-year path for novo nordisk (nvo) stock, supported by strong product momentum but tempered by...
This Promising GLP-1 Drug Could Renew Novo Nordisk Hope
Novo Nordisk has faced headwinds, but a new GLP-1 drug could change the game. This article breaks down what investors...
Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Novo Nordisk Slashing Prices Could Boost the Stock
Novo Nordisk slashing prices is drawing attention from investors who wonder how a price cut could actually lift the s...